Immunotherapy for Waldenstrom Macroglobulinemia

Some immunotherapy drugs are used to treat Waldenstrom macroglobulinemia (WM). Immunotherapy is the use of medicines to help a person’s own immune system recognize and destroy cancer cells.

Monoclonal antibodies to treat WM

Antibodies are proteins made by your immune system to help fight infections. Man-made versions of these proteins are called monoclonal antibodies. They can be designed to attack a specific target, such as a substance on the surface of lymphocytes (the cells in which Waldenstrom macroglobulinemia starts).

Monoclonal antibodies that attack CD20

Some monoclonal antibodies attack a protein called CD20 found on the surface of lymphocytes, including the WM cells. These drugs tell the lymphoma cell to die.

These drugs include:

  • Rituximab (Rituxan)
  • Obinutuzumab (Gazyva)

These drugs are given by infusion into a vein (IV) at the doctor’s office or clinic. They can be given alone or with chemotherapy or targeted therapy as part of treatment.

These drugs must be given carefully to people with Waldenstrom macroglobulinemia, because sometimes they actually raise the level of IgM in the blood at first, which can lead to problems with hyperviscosity (thickened blood).

Side effects during the infusion are common. These can include chills, fever, nausea, rashes, fatigue, and headaches. Unlike regular chemotherapy, rituximab doesn’t cause low blood counts or hair loss.

Monoclonal antibodies that attack CD38

Daratumumab is another drug used to treat WM. This monoclonal antibody attacks the cell-surface protein CD38 on lymphocytes. It may be used in combination with other chemo or targeted drugs.

Immunomodulating drugs to treat WM

Immunomodulating drugs are thought to work by boosting the immune system, but the exact way they work is not fully understood. 

They include:

  • Lenalidomide
  • Pomalidomide

These drugs may be tried as a treatment for Waldenstrom macroglobulinemia when other treatments haven’t worked.

Possible side effects include low blood counts and neuropathy (injury to the nerves causing difficulty moving or pain). Your cancer care team will monitor you closely for these side effects.

These drugs can also cause birth defects and should not be taken during pregnancy.

More information about immunotherapy

To learn more about how drugs that work on the immune system are used to treat cancer, see Cancer Immunotherapy.

To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.

side by side logos for American Cancer Society and American Society of Clinical Oncology

Developed by the American Cancer Society medical and editorial content team with medical review and contribution by the American Society of Clinical Oncology (ASCO).

Buske C, Castillo JJ, Abeykoon JP, et al. Report of consensus panel 1 from the 11th International Workshop on Waldenstrom's Macroglobulinemia on management of symptomatic, treatment-naïve patients. Semin Hematol. 2023;60(2):73-79.

Buske C, Dimopoulos MA, Grunenberg A, et al. Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. J Clin Oncol. 2023;41(14):2607-2616.

Buske C, Tedeschi A, Trotman J, et al. Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study. J Clin Oncol. 2022;40(1):52-62.

Castillo JJ, Treon SP. Chapter 92: Waldenstrom Macroglobulinemia/ Lymphoplasmacytic Lymphoma. In: Hoffman R, Benz EJ, Silberstein LE, eds. Hematology: Basic Principles and Practice. 8th ed. Philadelphia, PA. Elsevier; 2023.

Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019;134(23):2022-2035.

Grunenberg A, Buske C. How to manage waldenström's macroglobulinemia in 2024. Cancer Treat Rev. 2024;125:102715.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma. v.1.2026-June 24, 2025. Accessed at https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf on August 5, 2025.

Last Revised: November 17, 2025

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.